Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat

Biochemical and Biophysical Research Communications

Volumn 345, Issue 1, 2006, Pages 38-42

  Holecek, Milan ^a   Muthny, Tomas ^a   Kovarik, Miroslav ^a   Sispera, Ludek ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Amino acids; Inhibitor; Nutrition; Proteasome; Protein metabolism; Ubiquitin

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; PROTEASOME INHIBITOR;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CATABOLISM; COLON; CONTROLLED STUDY; DRUG EFFECT; JEJUNUM; KIDNEY; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RAT; SKELETAL MUSCLE; UBIQUITINATION;

AMINO ACIDS; ANIMALS; LEUPEPTINS; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOME; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 33646417085     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.04.053     Document Type: Article

References (27)

1. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2002) 373-428
2. Kisselev A.F., and Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8 (2001) 739-758
3. Richardson P.G., Hideshima T., and Anderson K.C. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10 (2003) 361-369
4. Tiao G., Fagan J.M., Samuels N., James J.H., Hudson H., Lieberman M., Fischer J.E., and Hasselgren P.O. Sepsis stimulates non-lysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle. J. Clin. Invest. 94 (1994) 2255-2264
5. Fischer D., Sun X., Gang G., Pritts T., and Hasselgren P.O. The gene expression of ubiquitin ligase E3α is upregulated in skeletal muscle during sepsis in rats. Potential role of glucocorticoids. Biochem. Biophys. Res. Commun. 267 (2000) 504-508
6. Attaix D., Ventadour S., Codran A., Bechet D., Taillandier D., and Combaret L. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem. 41 (2005) 173-186
7. Tisdale M.J. The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J. Support. Oncol. 3 (2005) 209-217
8. Tawa N.E., Odessey R., and Goldberg A.L. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J. Clin. Invest. 100 (1997) 197-203
9. Hobler S.C., Tiao G., Fischer J.E., Monaco J., and Hasselgren P.O. Sepsis-induced increase in muscle proteolysis is blocked by specific proteasome inhibitors. Am. J. Physiol. 274 (1998) R30-R37
10. Fang C.H., Li B.G., Tiao G., Wang J.J., Fischer J.E., and Hasselgren P.O. The molecular regulation of protein breakdown following burn injury is different in fast- and slow-twitch skeletal muscle. Int. J. Mol. Med. 1 (1998) 163-169
11. 3VS on protein metabolism in septic rats. Int. J. Exp. Pathol. 85 (2004) 365-371
12. 3VS on protein and amino acid metabolism in rat skeletal muscle. Physiol. Res. 54 (2005) 541-547
13. Fischer D., Gang G., Pritts T., and Hasselgren P.O. Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo. Biochem. Biophys. Res. Commun. 270 (2000) 215-221
14. Huang J., and Forsberg N.E. Role of calpain in skeletal muscle protein degradation. Proc. Nat. Acad. Sci. USA 95 (1998) 12100-12105
15. Du J., Wang X., Miereles C., Bailey J.L., Debigare R., Zheng B., Price S.R., and Mitch W.E. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J. Clin. Invest. 113 (2004) 115-123
16. Holecek M., Sprongl L., Skopec F., Andrys C., and Pecka M. Leucine metabolism in TNF-α- and endotoxin-treated rats: contribution of hepatic tissue. Am. J. Physiol. 273 (1997) E1052-E1058
17. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
18. Garlick P.K., Millward D.J., and James W.P.T. The diurnal response of muscle and liver protein synthesis in vivo in meal-fed rats. Biochem. J. 136 (1973) 935-945
19. Gomes-Marcondes M.C.C., and Tisdale M.J. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett. 180 (2002) 69-74
20. Bechet D., Tassa A., Taillandier D., Combaret L., and Attaix D. Lysosomal proteolysis in skeletal muscle. Int. J. Biochem. Cell Biol. 37 (2005) 2098-2114
21. Wallace A.D., and Cidlowski J.A. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signalling by glucocorticoids. J. Biol. Chem. 276 (2001) 42714-42721
22. Shibata T., Imaizumi T., Tamo W., Matsumiya T., Kumagai M., Cui X.F., Yoshida H., Takaya S., Fukuda I., and Satoh K. Proteasome inhibitor MG-132 enhances the expression of interleukin-6 in human umbilikal vein endothelial cells: involvement of MAP/ERK kinase. Immunol. Cell Biol. 80 (2002) 226-230
23. Joshi-Barve S., Barve S.S., Butt W., Klein J., and McClain C.J. Inhibition of proteasome function leads to NF-kappaB-independent Il-8 expression in human hepatocytes. Hepatology 38 (2003) 1178-1187
24. Kawazoe Y., Nakai A., Tanabe M., and Nagata K. Proteasome inhibition leads to the activation of all members of the heat-shock-factor family. Eur. J. Biochem. 255 (1998) 356-362
25. Nemeth Z.H., Wong H.R., Odoms K., Deitch E.A., Szabo C., Vizi E.S., and Hasko G. Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells. Mol. Pharmacol. 65 (2004) 342-349
26. Krebs N.E., and Hambidge K.M. Zinc metabolism and homeostasis: the application of tracer techniques to human zinc physiology. Biometals 14 (2001) 397-412
27. Cuschieri J., Gourlay D., Garcia I., Jelacic S., and Maier R.V. Implications of proteasome inhibition: an enhanced macrophage phenotype. Cell Immunol. 227 (2004) 140-147